All In Biotech

NDA 019339 · Hospira

Heparin Sodium 10,000 Units In Dextrose 5% In Plastic Container

Heparin Sodium · Injection

Last checked: Nov 19, 2026Latest source record: Feb 7, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1985

Mar 27, 1985

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,126

334 Phase 3, 112 recruiting

FAERS reports

14,122

11,112 serious, 2,661 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 25, 2026.

Heparin Sodium in 5% Dextrose Injection is indicated for: • Prophylaxis and treatment of venous thrombosis and pulmonary embolism • Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation • Treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation) • Prevention of clotting in arterial and cardiac surgery • Prophylaxis and treatment of peripheral arterial embolism • Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures. Heparin Sodium in 5% Dextrose Injection is indicated for: ( 1 ) • Prophylaxis and treatment of venous thrombosis and pulmonary embolism. • Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation. • Treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation). • Prevention of clotting in arterial and cardiac surgery. • Prophylaxis and treatment of peripheral arterial embolism. • Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures.

Mechanism: Heparin interacts with the naturally occurring plasma protein, antithrombin III, to induce a conformational change, which markedly enhances the serine protease activity of antithrombin III, thereby inhibiting the activated coagulation factors involved in the closing sequence, particularly Xa and IIa. Small amounts of heparin inhibit Factor Xa, and larger amounts inhibit thrombin (Factor IIa). Heparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor. Heparin does not have fibrinolytic activity; therefore, it will not lyse...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 27, 1985 Original approval · Type 5 - New Formulation or New Manufacturer
4 products under this application
  • HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER · HEPARIN SODIUM 10,000 UNITS/100ML · INJECTABLE, INJECTION · Prescription · TE AP
  • HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER · HEPARIN SODIUM 5,000 UNITS/100ML · INJECTABLE, INJECTION · Prescription
  • HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER · HEPARIN SODIUM 5,000 UNITS/100ML · INJECTABLE, INJECTION · Prescription · TE AP
  • HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER · HEPARIN SODIUM 10,000 UNITS/100ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Heparin" as an intervention, any sponsor and status, largest first.

All 1,126 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • heparin-induced thrombocytopenia1,310
  • drug ineffective1,051
  • off label use787
  • nausea757
  • drug hypersensitivity644
  • vomiting620
  • hypotension576
  • dyspnoea559
  • pulmonary embolism523
  • sepsis505
  • pyrexia499
  • anaemia492

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004464
2005225
2006189
2007127
20081,029
2009247
2010472
2011403
2012361
2013329
2014276
2015369
2016420
2017547
2018649
2019796
2020705
2021975
20221,143
20231,256
20241,027
20251,003
20261,110

Recalls

1 FDA enforcement reports for this application.

  • Jun 6, 2014 · Class II · Terminated

    Lack of Assurance of Sterility: Confirmed consumer report of fluid leaking from primary container of bag.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7,572 on PubMed

Sponsor: Pfizer · Also marketed as Heparin Sodium 12,500 Units In Dextrose 5% In Plastic Container, Heparin Sodium 25,000 Units In Dextrose 5% In Plastic Container

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.